UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 50

Sortiert nach

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

Annals of oncology, 2021-05, Vol.32 (5), p.661-672

2021

Link zum Volltext

Verfügbarkeit prüfen

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence

Annals of oncology, 2016-07, Vol.27 (7), p.1241-1248

2016

Link zum Volltext

Verfügbarkeit prüfen

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Annals of oncology, 2020-11, Vol.31 (11), p.1526-1535

2020

Link zum Volltext

Verfügbarkeit prüfen

Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer

Annals of oncology, 2017-10, Vol.28 (10), p.2420-2428

2017

Link zum Volltext

Verfügbarkeit prüfen

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

Annals of oncology, 2018-09, Vol.29 (9), p.1939-1947

2018

Link zum Volltext

Verfügbarkeit prüfen

Age at diagnosis and distant metastasis in breast cancer – A surprising inverse relationship: Purushotham A, Shamil E, Cariati M, et al (King's College London, UK; et al) Eur J Cancer 50:1697-1705, 2014

Breast diseases, 2015, Vol.26 (3), p.222-223

Litton, J.K.

2015

Link zum Volltext

Verfügbarkeit prüfen

19P Pharmacodynamic activity of [18F]-fluorthanatrace poly(ADP-ribose) polymerase (PARP) PET in BRCA1/2-mutated breast cancer patients receiving talazoparib

ESMO open, 2024-02, Vol.9, p.102350, Article 102350

2024

Link zum Volltext

Verfügbarkeit prüfen

21P Germline and somatic variants in DNA DMAGE repair (DDR) genes in patients with untreated, early-stage triple negative breast cancers (TNBC)

Annals of oncology, 2020-05, Vol.31, p.S23-S24

2020

Link zum Volltext

Verfügbarkeit prüfen

273P Talazoparib (TALA) for patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC): Characteristics of patients who experienced hematologic toxicity in the phase III EMBRACA trial

Annals of oncology, 2021-09, Vol.32, p.S482-S482

2021

Link zum Volltext

Verfügbarkeit prüfen

272P Outcomes of patients (pts) who had received prior platinum (PP) therapy in the phase III EMBRACA trial of talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC)

Annals of oncology, 2021-09, Vol.32, p.S481-S481

2021

Link zum Volltext

Verfügbarkeit prüfen

Bintrafusp alfa (M7824) and eribulin mesylate in treating patients with metastatic triple negative breast cancer (TNBC)(NCT03579472)

Annals of oncology, 2019-10, Vol.30, p.v139

2019

Link zum Volltext

Verfügbarkeit prüfen

383TiP - Bintrafusp alfa (M7824) and eribulin mesylate in treating patients with metastatic triple negative breast cancer (TNBC)(NCT03579472)

Annals of oncology, 2019-10, Vol.30, p.v139-v139

2019

Link zum Volltext

Verfügbarkeit prüfen

Incidence, Risk Factors, and Obstetrical Outcomes of Women with Breast Cancer in Pregnancy

Breast diseases, 2013-01, Vol.24 (2), p.140-141

Litton, J.K.

2013

Link zum Volltext

Verfügbarkeit prüfen

Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome: Goldrat O, Kroman N, Peccatori FA, et al (Erasme Hosp, Brussels, Belgium; Righospitalet, Copenhagen, Denmark; European Inst of Oncology, Milan, Italy; et al) Eur J Cancer 51:1490-1496, 2015

Breast diseases, 2016, Vol.27 (1), p.29-30

2016

Link zum Volltext

Verfügbarkeit prüfen

Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer

Annals of oncology, 2013-08, Vol.24 (8), p.1999-2004

2013

Link zum Volltext

Verfügbarkeit prüfen

Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial

Annals of oncology, 2018-10, Vol.29, p.viii97-viii97

2018

Link zum Volltext

Verfügbarkeit prüfen

Significant Improvement in Regional Recurrence in Young Patients with Breast Cancer Treated with Comprehensive Nodal Irradiation

International journal of radiation oncology, biology, physics, 2008, Vol.72 (1), p.S89-S89

2008

Link zum Volltext

Verfügbarkeit prüfen

Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials

Annals of oncology, 2018-10, Vol.29, p.viii97-viii97

2018

Link zum Volltext

Verfügbarkeit prüfen

Exemestane for Breast-Cancer Prevention in Postmenopausal Women: Goss PE, for the NCIC CTG MAP.3 Study Investigators (Massachusetts General Hosp Cancer Ctr, Boston; et al) N Engl J Med 364:2381-2391, 2011

Breast diseases, 2012, Vol.23 (3), p.226-227

Litton, J.K.

2012

Link zum Volltext

Verfügbarkeit prüfen

98O The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumour infiltrating lymphocytes (sTIL)

Annals of oncology, 2020-05, Vol.31, p.S49-S49

2020

Link zum Volltext

Verfügbarkeit prüfen

Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation

Annals of oncology, 2018-10, Vol.29, p.viii91-viii91

2018

Link zum Volltext

Verfügbarkeit prüfen

Responses and durability of clinical benefit in triple negative breast cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy

Annals of oncology, 2018-10, Vol.29, p.viii407-viii408

2018

Link zum Volltext

Verfügbarkeit prüfen

EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis

Annals of oncology, 2018-10, Vol.29, p.viii96-viii97

2018

Link zum Volltext

Verfügbarkeit prüfen

Age at diagnosis and distant metastasis in breast cancer – A surprising inverse relationship

Breast diseases, 2015, Vol.26 (3), p.222-223

Litton, J.K.

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(50)

Sprache

Englisch
(50)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Humans
(9)
Oncology
(8)
Breast Cancer
(7)
Female
(7)
Middle Aged
(7)
Adult
(6)
Aged
(6)
Original
(5)
Aged, 80 And Over
(4)
Biological And Medical Sciences
(4)
Breast Neoplasms - Drug Therapy
(4)
Gynecology. Andrology. Obstetrics
(4)
Mammary Gland Diseases
(4)
Medical Sciences
(4)
Tumors
(4)
Antineoplastic Agents
(3)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)
Breast Neoplasms - Genetics
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(23)
Breast Diseases
(20)
Cancer
(1)
Clinical Breast Cancer
(1)
Esmo Open
(1)
Gynecologic Oncology
(1)
International Journal Of Radiation Oncology, Biology, Physics
(1)
New Forests
(1)
Restoration Ecology
(1)

4 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

Age at diagnosis and distant metastasis in breast cancer – A surprising inverse relationship: Purushotham A, Shamil E, Cariati M, et al (King's College London, UK; et al) Eur J Cancer 50:1697-1705, 2014

19P Pharmacodynamic activity of [18F]-fluorthanatrace poly(ADP-ribose) polymerase (PARP) PET in BRCA1/2-mutated breast cancer patients receiving talazoparib

21P Germline and somatic variants in DNA DMAGE repair (DDR) genes in patients with untreated, early-stage triple negative breast cancers (TNBC)

273P Talazoparib (TALA) for patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC): Characteristics of patients who experienced hematologic toxicity in the phase III EMBRACA trial

272P Outcomes of patients (pts) who had received prior platinum (PP) therapy in the phase III EMBRACA trial of talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC)

Bintrafusp alfa (M7824) and eribulin mesylate in treating patients with metastatic triple negative breast cancer (TNBC)(NCT03579472)

383TiP - Bintrafusp alfa (M7824) and eribulin mesylate in treating patients with metastatic triple negative breast cancer (TNBC)(NCT03579472)

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer

Incidence, Risk Factors, and Obstetrical Outcomes of Women with Breast Cancer in Pregnancy

Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome: Goldrat O, Kroman N, Peccatori FA, et al (Erasme Hosp, Brussels, Belgium; Righospitalet, Copenhagen, Denmark; European Inst of Oncology, Milan, Italy; et al) Eur J Cancer 51:1490-1496, 2015

Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer

Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial

Significant Improvement in Regional Recurrence in Young Patients with Breast Cancer Treated with Comprehensive Nodal Irradiation

Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials

Exemestane for Breast-Cancer Prevention in Postmenopausal Women: Goss PE, for the NCIC CTG MAP.3 Study Investigators (Massachusetts General Hosp Cancer Ctr, Boston; et al) N Engl J Med 364:2381-2391, 2011

98O The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumour infiltrating lymphocytes (sTIL)

Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation

Responses and durability of clinical benefit in triple negative breast cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy

EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis

Age at diagnosis and distant metastasis in breast cancer – A surprising inverse relationship

Suchergebnisse filtern